B+
Bull case
20%
Probability
Target price
$117.00
Analysis reference price unavailable
Analysis 2026-05-29 · RankAlpha Sentiment Codex
MLAB
Mesa LaboratoriesDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The bull case is that FY26 closed with modest revenue growth, a sharp AOI margin step-up, and lower leverage, while management signaled that SDC strength and easing export controls could help FY27 core growth recover. If the H1 guidance update confirms the BPD problems are temporary rather than structural, the earnings power story improves meaningfully.
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.3.
What can break
BPD commercial execution and export-control-related shipping delays remain the clearest near-term operating risk; management explicitly flagged both in the release. [#8-K-2026-05-27]
Momentum
93
Value
63
Sentiment
28
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $101.00 · Bull $117.00 · Bear $78.00Analysis 2026-05-29; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-26 • Vendor: Data Vendor v1
Scores
As of 2026-10-26 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-29 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-26
Investment thesis
As of 2026-10-26
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-26. Definitions
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $125.00
Why
Momentum93 · Δ7d -0.7
Value63 · Δ7d -0.3
Sentiment28 · Δ7d -4.8
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Value remains the lead driver in the composite, 7D delta -0.3.
Contradictions & invalidation
- • BPD commercial execution and export-control-related shipping delays remain the clearest near-term operating risk; management explicitly flagged both in the release. [#8-K-2026-05-27]
- • Clinical Genomics had prior pressure in the December 2025 10-Q, including China-related weakness, so the better current-quarter tone there is encouraging but not yet a full normalization story. [#10-Q-2026-02-03]
- • The bear case is that the print was still mixed: BPD commercial execution and export-control shipping delays were a clear drag, and management did not yet give rest-of-year guidance.
Catalyst clock
2026-05-27
4Q/FY26 print confirmed stronger profitability but mixed operating execution
Lead driver: Value · See fundamentals
Momentum
93
8% active weight
Current posture
7d trendFlat
Δ7d
-0.7
Δ21d
+2.6
Value
63
47% active weight
Current posture
7d trendFlat
Δ7d
-0.3
Δ21d
-0.3
Sentiment
28
45% active weight
Current posture
7d trendSoftening
Δ7d
-4.8
Δ21d
-2.3
Why this grade
Composite grade D. Momentum 92.5 / Value 63.0 / Sentiment 28.4
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-05-29. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$101.00
Analysis reference price unavailable
Analysis 2026-05-29 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$78.00
Analysis reference price unavailable
Analysis 2026-05-29 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-26
Fundamentals (TTM)
As of 2026-10-26
Market Cap
$726.74M
Beta
0.88
Shares Out
5.6M
P/E (TTM) · Derived
106.7
P/S (TTM)
1.96
P/FCF (TTM)
17.38
Rev YoY
+1.0%
EPS YoY
-42.4%
Gross Margin
+57.4%
Op Margin
+9.0%
Net Debt
$141.9M
Current Ratio
1.79
As of 2026-10-26 • Updated nightlySource: Internal modelMethods & Data